Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib
- 78 Downloads
The multikinase inhibitor sorafenib (SOR) is used to treat patients with hepatocellular and renal carcinomas. SOR undergoes CYP-mediated biotransformation to a pharmacologically active N-oxide metabolite (SNO) that has been shown to accumulate to varying extents in individuals. Kinase inhibitors like SOR are frequently coadministered with a range of other drugs to improve the efficacy of anticancer drug therapy and to treat comorbidities. Recent evidence has suggested that SNO is more effective than SOR as an inhibitor of CYP3A4-mediated midazolam 1′-hydroxylation. CYP2D6 is also reportedly inhibited by SOR. The present study assessed the possibility that SNO might contribute to CYP2D6 inhibition. The inhibition kinetics of CYP2D6-mediated dextromethorphan O-demethylation were analyzed in human hepatic microsomes, with SNO found to be ~ 19-fold more active than SOR (Kis 1.8 ± 0.3 μM and 34 ± 11 μM, respectively). Molecular docking studies of SOR and SNO were undertaken using multiple crystal structures of CYP2D6. Both molecules mediated interactions with key amino acid residues in putative substrate recognition sites of CYP2D6. However, a larger number of H-bonding interactions was noted between the N-oxide moiety of SNO and active site residues that account for its greater inhibition potency. These findings suggest that SNO has the potential to contribute to pharmacokinetic interactions involving SOR, perhaps in those individuals in whom SNO accumulates.
KEY WORDSCYP2D6 inhibition dextromethorphan O-demethylation metabolite inhibition molecular docking sorafenib sorafenib N-oxide
area under the serum concentration versus time curve
maximal serum concentration
substrate recognition site
Technical contributions in aspects of the study from Dr. S. Cui and Ms. K Bourget are also acknowledged. The supply of the human liver samples used in this study by Dr. J George is also gratefully acknowledged.
This study is financially supported by the Cancer Council NSW (grants RG09-14 and IG11-33). PCN is supported by the Flinders Centre for Innovation in Cancer (FCIC) and Flinders Medical Centre (FMC) Foundation through an Early Career Research Grant.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–8. https://doi.org/10.1158/0008-5472.CAN-06-1377.CrossRefPubMedGoogle Scholar
- 3.Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, et al. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer. 2012;48:465–74. https://doi.org/10.1016/j.ejca.2011.12.026.CrossRefPubMedGoogle Scholar
- 6.Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426–37. https://doi.org/10.1634/theoncologist.12-4-426.CrossRefPubMedGoogle Scholar
- 7.Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008;99:1492–8. https://doi.org/10.1111/j.1349-7006.2008.00837.x.CrossRefPubMedGoogle Scholar
- 8.Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29:3293–300. https://doi.org/10.1200/JCO.2011.34.7427.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, et al. Phase I/II trial of sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer. PLoS One. 2016;11:e0167906. https://doi.org/10.1371/journal.pone.0167906.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Cantrill E, Murray M, Mehta I, Farrell GC. Down-regulation of the male-specific steroid 16α-hydroxylase, cytochrome P-450UT-A, in male rats with portal bypass: relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis. J Clin Invest. 1989;83:1211–6. https://doi.org/10.1172/JCI114003.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Ghassabian S, Chetty M, Tattam BN, Glen J, Rahme J, Stankovic Z, et al. A high-throughput assay using liquid chromatography/tandem mass spectrometry for simultaneous in vivo phenotyping of five major cytochrome P450 enzymes in patients. Ther Drug Monit. 2009;31:239–46. https://doi.org/10.1097/FTD.0b013e318197e1bf.CrossRefPubMedGoogle Scholar
- 17.von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther. 1994;268:1278–83.Google Scholar
- 28.Ortiz de Montellano PR, Correia MA. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu Rev Pharmacol Toxicol. 1983;23:481–503. https://doi.org/10.1146/annurev.pa.23.040183.002405.CrossRefGoogle Scholar
- 35.Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol. 2000;49:244–53. https://doi.org/10.1046/j.1365-2125.2000.00134.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Giri P, Naidu S, Patel N, Patel H, Srinivas NR. Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. Eur J Drug Metab Pharmacokinet. 2017;42:677–88. https://doi.org/10.1007/s13318-016-0385-7.CrossRefPubMedGoogle Scholar
- 40.Bapiro TE, Hasler JA, Ridderström M, Masimirembwa CM. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol. 2002;64:1387–98. https://doi.org/10.1016/s0006-2952(02)01351-5.CrossRefPubMedGoogle Scholar
- 41.Venhorst J, ter Laak AM, Commandeur JN, Funae Y, Hiroi T, Vermeulen NP. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. J Med Chem. 2003;46:74–86. https://doi.org/10.1021/jm0209578.CrossRefPubMedGoogle Scholar
- 45.Clive S, Woo MM, Nydam T, Kelly L, Squier M, Kagan M. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol. 2012;70:513–22. https://doi.org/10.1007/s00280-012-1940-9.CrossRefPubMedGoogle Scholar
- 46.Knieling F, Waldner MJ, Goertz RS, Strobel D. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ Case Rep. 2012;2012:bcr2012007576. https://doi.org/10.1136/bcr-2012-007576.CrossRefPubMedPubMedCentralGoogle Scholar
- 47.Gahr S, Wissniowski T, Zopf S, Strobel D, Pustowka A, Ocker M. Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. J Cancer. 2012;3:158–65. https://doi.org/10.7150/jca.4211.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Massarweh S, Moss J, Wang C, Romond E, Slone S, Weiss H, et al. Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. Future Oncol. 2014;10:2435–48. https://doi.org/10.2217/fon.14.99.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011;68:1111–8. https://doi.org/10.1007/s00280-011-1585-0.CrossRefPubMedGoogle Scholar